

CITATION REPORT

List of articles citing

Endothelial dysfunction and cardiovascular risk profile
in nonalcoholic fatty liver disease

DOI: 10.1002/hep.20781
Hepatology, 2005, 42, 473-80.

Source: <https://exaly.com/paper-pdf/38329919/citation-report.pdf>

Version: 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
519	Circulatory dysfunction in NAFLD--which is first, which is last, and what do we do in between?. <i>Hepatology</i> , 2005 , 42, 270-2	11.2	7
518	Associations between liver histology and early carotid atherosclerosis in subjects with nonalcoholic fatty liver disease. <i>Hepatology</i> , 2005 , 42, 974-5; discussion 975	11.2	21
517	Potential role of CB2 receptors in Cannabis smokers with chronic hepatitis C. <i>Hepatology</i> , 2005 , 42, 975-6; author reply 976-7	11.2	13
516	Reply:. <i>Hepatology</i> , 2005 , 42, 975-975	11.2	10
515	Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. 2005 , 54, 3541-6		449
514	Association Between Sonographic Fatty Liver and Ischemic Electrocardiogram Among Non-obese Taiwanese Male Adults. 2006 , 14, 58-64		2
513	Metabolic and adipokine profile of Chinese patients with nonalcoholic fatty liver disease. 2006 , 4, 1154-61		152
512	gamma-Glutamyltransferase is a promising biomarker for cardiovascular risk. 2006 , 67, 1060-4		36
511	Prevalence and risk factors of nonalcoholic fatty liver disease in an adult population of taiwan: metabolic significance of nonalcoholic fatty liver disease in nonobese adults. 2006 , 40, 745-52		215
510	Current World Literature. 2006 , 11, 311-350		
509	Bibliography. Current world literature. Hyperlipidaemia and cardiovascular disease. 2006 , 17, 445-75		
508	Cardiac abnormalities as a new manifestation of nonalcoholic fatty liver disease: echocardiographic and tissue Doppler imaging assessment. 2006 , 40, 949-55		128
507	Increased prevalence of cardiovascular disease in Type 2 diabetic patients with non-alcoholic fatty liver disease. 2006 , 23, 403-9		125
506	Nutritional aspects of non-alcoholic steatohepatitis treatment. 2006 , 63, 79-90		5
505	Prevalence of undiagnosed diabetes and postchallenge hyperglycaemia in Chinese patients with non-alcoholic fatty liver disease. 2006 , 24, 1215-22		80
504	Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. <i>Hepatology</i> , 2006 , 43, 682-9	11.2	381
503	Elevated serum alanine aminotransferase activity and calculated risk of coronary heart disease in the United States. <i>Hepatology</i> , 2006 , 43, 1145-51	11.2	178

502	Statins and hepatic steatosis: perspectives from the Dallas Heart Study. <i>Hepatology</i> , 2006 , 44, 466-71	11.2	133
501	A low-carbohydrate diet rapidly and dramatically reduces intrahepatic triglyceride content. <i>Hepatology</i> , 2006 , 44, 487-8	11.2	32
500	Assessing the outcome of nonalcoholic steatohepatitis? It's time to get serious. <i>Hepatology</i> , 2006 , 44, 802-5	11.2	52
499	Liver steatosis coexists with myocardial insulin resistance and coronary dysfunction in patients with type 2 diabetes. 2006 , 291, E282-90		124
498	Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease. 2006 , 29, 1325-30		312
497	Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. 2007 , 30, 2119-21		395
496	Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study. 2007 , 102, 1251-8		234
495	The proinflammatory phenotype of PECAM-1-deficient mice results in atherogenic diet-induced steatohepatitis. 2007 , 293, G1205-14		30
494	Concomitant Occurrence of Non-Alcoholic Fatty Liver Disease and Cholelithiasis. 2007 , 1, 353-360		1
493	Hemodynamic evaluation before liver transplantation: insights into the portal hypertensive syndrome. 2007 , 41 Suppl 3, S323-9		24
492	Non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease: an open question. 2007 , 17, 684-98		56
491	Evaluation and management of obesity-related nonalcoholic fatty liver disease. 2007 , 4, 432-41		74
490	Differences and similarities in early atherosclerosis between patients with non-alcoholic steatohepatitis and chronic hepatitis B and C. 2007 , 46, 1126-32		133
489	Non-alcoholic fatty liver disease as a determinant of cardiovascular disease. 2007 , 190, 18-9; author reply 20-1		12
488	Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. 2007 , 191, 235-40		431
487	Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. 2007 , 30, 1212-8		709
486	Epidemiology and natural history of NAFLD and NASH. 2007 , 11, 1-16, vii		334
485	Metabolic syndrome and NASH. 2007 , 11, 105-17, ix		99

484	Increased mediastinal fat and impaired left ventricular energy metabolism in young men with newly found fatty liver. <i>Hepatology</i> , 2008 , 47, 51-8	11.2	157
483	Effects of nonalcoholic fatty liver disease on the development of metabolic disorders. 2007 , 22, 1086-91		135
482	What are the risk factors and settings for non-alcoholic fatty liver disease in Asia-Pacific?. 2007 , 22, 794-800		196
481	Non-alcoholic fatty liver disease, the metabolic syndrome and the risk of cardiovascular disease: the plot thickens. 2007 , 24, 1-6		170
480	Fatty liver now, diabetes and heart attack later? The liver as a barometer of metabolic health. 2007 , 22, 967-9		35
479	Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review. 2007 , 157, 649-55		236
478	Liver: an alarm for the heart?. 2007 , 27, 891-4		64
477	Hypercoagulation and thrombophilia in liver disease. 2008 , 6, 2-9		120
476	[Metabolic fatty liver diseases: hepatic consequences of the metabolic syndrome]. 2007 , 31, 1127-34		2
475	NASH and the risk of cirrhosis and hepatocellular carcinoma in type 2 diabetes. 2007 , 7, 175-80		46
474	Nonalcoholic fatty liver disease and cardiovascular disease risk. 2007 , 7, 181-7		28
473	Role of growth hormone, insulin-like growth factor 1 and insulin-like growth factor-binding protein 3 in development of non-alcoholic fatty liver disease. 2007 , 1, 287-94		81
472	Oxidative stress and antioxidant defenses in serum of patients with non-alcoholic steatohepatitis. 2007 , 40, 776-80		81
471	Evaluation of metabolic syndrome frequency and carotid artery intima-media thickness as risk factors for atherosclerosis in patients with nonalcoholic fatty liver disease. <i>Digestive Diseases and Sciences</i> , 2008 , 53, 1352-7	4	46
470	Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon?. 2008 , 51, 1947-53		342
469	Statins in liver disease: a molehill, an iceberg, or neither?. <i>Hepatology</i> , 2008 , 48, 662-9	11.2	97
468	NASH predicts plasma inflammatory biomarkers independently of visceral fat in men. 2008 , 16, 1394-9		152
467	Endothelial dysfunction in Turkish patients with non-alcoholic fatty liver disease. 2008 , 38, 183-9		29

466	Endothelial dysfunction in Turkish patients with non-alcoholic fatty liver disease. 2008 , 38, 299-300; author reply 300-1	0
465	Reply. 2008 , 38, 300-301	
464	Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects. 2008 , 134, 1369-75	403
463	Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease. 2008 , 135, 1935-44, 1944.e1	242
462	Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study. 2008 , 103, 2263-71	255
461	Clinical and pathologic risk factors for atherosclerosis in cirrhosis: a comparison between NASH-related cirrhosis and cirrhosis due to other aetiologies. 2008 , 49, 595-9	85
460	Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review. 2008 , 49, 600-7	315
459	Carotid artery intima-media thickness in nonalcoholic fatty liver disease. 2008 , 121, 72-8	164
458	Validation of the NAFLD fibrosis score in a Chinese population with low prevalence of advanced fibrosis. 2008 , 103, 1682-8	82
457	Nonalcoholic fatty liver disease and carotid atherosclerosis in children. 2008 , 63, 423-7	136
456	Prevalence of elevated liver enzymes in Type 2 diabetes mellitus and its association with the metabolic syndrome. 2008 , 31, 146-52	43
455	Identification and characterization of metabolically benign obesity in humans. 2008 , 168, 1609-16	736
454	Association between non-alcoholic fatty liver disease and cardiovascular disease: a first message should pass. 2008 , 103, 3036-8	18
453	Fatty liver is independently associated with alterations in circulating HDL2 and HDL3 subfractions. 2008 , 31, 366-8	49
452	Causes and metabolic consequences of Fatty liver. 2008 , 29, 939-60	394
451	Die frühe Fettleber und ihre Folgen. 2008 , 3, 105-111	
450	The epidemiology of nonalcoholic fatty liver disease: a global perspective. 2008 , 28, 339-50	547
449	Nonalcoholic fatty liver disease: from clinical recognition to treatment. 2008 , 2, 59-79	10

448	Recent advances in nonalcoholic fatty liver disease. 2008 , 24, 320-7		72
447	Nonalcoholic fatty liver disease: the potential role of nutritional management. 2008 , 11, 766-73		23
446	[Metabolic characteristics and associated factors of nonalcoholic fatty liver disease diagnosed at medical checkups]. 2008 , 28, 244-50		3
445	Altered clot kinetics in patients with non-alcoholic fatty liver disease. 2009 , 8, 331-338		20
444	Nonalcoholic fatty liver disease and its association with cardiovascular disease. 2009 , 8, S40-S43		48
443	Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene. 2009 , 58, 2616-23		261
442	Nonalcoholic fatty liver disease as a comorbidity of childhood obesity. 2009 , 3, 271-281		39
441	Viewpoints on the way to a consensus session: where does insulin resistance start? The liver. 2009 , 32 Suppl 2, S164-7		34
440	High cardiorespiratory fitness is an independent predictor of the reduction in liver fat during a lifestyle intervention in non-alcoholic fatty liver disease. 2009 , 58, 1281-8		192
439	Association of gamma-glutamyltransferase with cardiovascular risk: a prognostic outlook. 2009 , 40, 318-20		13
438	Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. <i>Hepatology</i> , 2009 , 49, 306-17	11.2	406
437	Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population. <i>Hepatology</i> , 2009 , 49, 1537-44	11.2	248
436	The plasma lipidomic signature of nonalcoholic steatohepatitis. <i>Hepatology</i> , 2009 , 50, 1827-38	11.2	431
435	Glucose abnormalities in non-alcoholic fatty liver disease and chronic hepatitis C virus infection: the role of iron overload. 2009 , 25, 403-10		19
434	Hepatic steatosis, carotid atherosclerosis and metabolic syndrome: the STEATO Study. 2009 , 44, 1156-61		11
433	Relationships of PAI-1 levels to central obesity and liver steatosis in a sample of adult male population in southern Italy. 2009 , 4, 315-23		22
432	Influence of visceral obesity and liver fat on vascular structure and function in obese subjects. 2009 , 17, 1783-8		50
431	Non-alcoholic fatty liver disease from pathogenesis to management: an update. 2010 , 11, 430-45		128

430	An association between non-alcoholic fatty liver disease and polycystic ovarian syndrome. 2009 , 24, 243-7	74	
429	Clues from the carotids: an appraisal of cardiovascular disease risk in non-alcoholic fatty liver disease. 2009 , 24, 1315-7	2	
428	Morbidity and mortality following coronary artery bypass graft surgery in patients with cirrhosis: a population-based study. 2009 , 29, 1141-51	49	
427	A diagnostic model to differentiate simple steatosis from nonalcoholic steatohepatitis based on the likelihood ratio form of Bayes theorem. 2009 , 42, 624-9	18	
426	Relationship between cerebral arterial pulsatility and carotid intima media thickness in diabetic and non-diabetic patients with non-alcoholic fatty liver disease. 2009 , 32, 63-8	11	
425	Association of serum uric acid level with non-alcoholic fatty liver disease: a cross-sectional study. 2009 , 50, 1029-34	182	
424	Second-hand smoke stimulates lipid accumulation in the liver by modulating AMPK and SREBP-1. 2009 , 51, 535-47	79	
423	Non-alcoholic fatty liver disease: is bariatric surgery the answer?. 2009 , 13, 689-710	45	
422	Long-term follow-up of patients with nonalcoholic fatty liver. 2009 , 7, 234-8	554	
421	Hypercoagulation in liver disease. 2009 , 13, 109-116	38	
420	Recent advances in nonalcoholic fatty liver disease. 2009 , 25, 230-7	53	
419	Trends in nonalcoholic fatty liver disease-related hospitalizations in US children, adolescents, and young adults. 2009 , 48, 597-603	25	
418	Non-Alcoholic Fatty Liver Disease. 119-134	4	
417	Non-alcoholic Fatty Liver Disease and Cardiovascular Disease Risk. 2010 , 4, 32-39	4	
416	Levels of soluble CD40 ligand and P-Selectin in nonalcoholic fatty liver disease. <i>Digestive Diseases and Sciences</i> , 2010 , 55, 1128-34	4	9
415	Association between nonalcoholic fatty liver disease and coronary artery calcification. <i>Digestive Diseases and Sciences</i> , 2010 , 55, 1752-60	4	80
414	The inflamed liver and atherosclerosis: a link between histologic severity of nonalcoholic fatty liver disease and increased cardiovascular risk. <i>Digestive Diseases and Sciences</i> , 2010 , 55, 2644-50	4	85
413	Functional and morphological vascular changes in pediatric nonalcoholic fatty liver disease. <i>Hepatology</i> , 2010 , 52, 1643-51	11.2	74

412	The Role of Biobanks for the Understanding of GeneEnvironment Interactions. 2010 , 51-62	
411	The severity of non-alcoholic fatty liver disease correlates with high sensitivity C-reactive protein value and is independently associated with increased cardiovascular risk in healthy population. 2010 , 43, 1399-404	41
410	Lack of association between peroxisome proliferator-activated receptors alpha and gamma2 polymorphisms and progressive liver damage in patients with non-alcoholic fatty liver disease: a case control study. 2010 , 10, 102	46
409	Hypercholesterolemia and microvascular dysfunction: interventional strategies. 2010 , 7, 54	82
408	Carotid Intima-media thickness in childhood and adolescent obesity relations to abdominal obesity, high triglyceride level and insulin resistance. 2010 , 7, 278-83	40
407	Increased arterial stiffness and impaired endothelial function in nonalcoholic Fatty liver disease: a pilot study. 2010 , 23, 1183-9	89
406	Severity of liver injury and atherogenic lipid profile in children with nonalcoholic fatty liver disease. 2010 , 67, 665-70	52
405	Environmental and genetic determinants of fatty liver in humans. 2010 , 28, 169-78	29
404	Role of microRNAs in non-alcoholic steatohepatitis. 2010 , 16, 1952-7	19
403	Insulin resistance in nonalcoholic fatty liver disease. 2010 , 16, 1941-51	238
402	Presence of coronary plaques in patients with nonalcoholic fatty liver disease. 2010 , 254, 393-400	145
401	Mean platelet volume and its relationship with carotid atherosclerosis in subjects with non-alcoholic fatty liver disease. 2010 , 115, 253-9	34
400	Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. 2010 , 363, 1341-50	1353
399	Male sexual disturbances in liver diseases: what do we know?. 2010 , 33, 501-5	12
398	Hemostasis and thrombosis in patients with liver disease: the ups and downs. 2010 , 53, 362-71	275
397	A position statement on NAFLD/NASH based on the EASL 2009 special conference. 2010 , 53, 372-84	726
396	Normal range of alanine aminotransferase concentration is associated with carotid atherosclerosis. 2010 , 88, 111-6	10
395	Ectopic fat and cardiovascular disease: what is the link?. 2010 , 20, 481-90	114

394	Enfermedad del hígado graso no alcohólico y riesgo cardiovascular. 2010 , 22, 259-271	
393	Circulating levels and hepatic expression of molecular mediators of atherosclerosis in nonalcoholic fatty liver disease. 2010 , 209, 585-91	90
392	Coronary flow reserve is impaired in patients with nonalcoholic fatty liver disease: association with liver fibrosis. 2010 , 211, 182-6	70
391	The role of non-alcoholic fatty liver disease in cardiovascular disease. 2010 , 28, 210-3	50
390	Oxidative stress is activated by free fatty acids in cultured human hepatocytes. 2011 , 9, 397-401	38
389	Nonalcoholic Fatty Liver Disease. 2011 , 868-907	1
388	Beyond hereditary hemochromatosis: new insights into the relationship between iron overload and chronic liver diseases. 2011 , 43, 89-95	58
387	Nifedipine prevents hepatic fibrosis in a non-alcoholic steatohepatitis model induced by an L-methionine-and choline-deficient diet. 2012 , 5, 37-40	5
386	Endocrine diseases and the liver. 2011 , 15, 55-67	32
385	Venous thromboembolism with chronic liver disease. 2011 , 124, 64-8	30
384	[Non-alcoholic fatty liver disease. How and who to screen]. 2011 , 34, 278-88	
383	Iron in fatty liver and in the metabolic syndrome: a promising therapeutic target. 2011 , 55, 920-32	205
382	Endothelial dysfunction and non-alcoholic liver steatosis in hypertensive patients. 2011 , 21, 485-91	21
381	Serum ferritin levels are associated with vascular damage in patients with nonalcoholic fatty liver disease. 2011 , 21, 568-75	62
380	MicroPPARTicle in atherosclerosis: guilty or innocent by-standers?. 2011 , 218, 21-2	1
379	Gamma-glutamyltransferase to determine cardiovascular risk: shifting the paradigm forward. 2011 , 18, 177-81	50
378	Evaluation of carotid intima-media thickness and flow-mediated dilatation in middle-aged patients with nonalcoholic fatty liver disease. 2011 , 7, 661-5	18
377	Ectopic fat storage, insulin resistance, and hypertension. 2011 , 17, 3074-80	13

376	Coffee Consumption is Associated with a Lower Incidence of Fatty Liver in Middle-aged Men. 2011 , 57, 406-413		5
375	Nutrition and physical activity in NAFLD: an overview of the epidemiological evidence. 2011 , 17, 3377-89		187
374	Recent insights into the relationship between inflammatory liver diseases and atherosclerosis. 2011 , 59, 904-11		12
373	Outcomes after curative treatment for cryptogenic cirrhosis-associated hepatocellular carcinoma satisfying the Milan criteria. 2011 , 26, 1417-24		17
372	The association between the metabolic syndrome and alanine amino transferase is mediated by insulin resistance via related metabolic intermediates (the Cohort on Diabetes and Atherosclerosis Maastricht [CODAM] study). 2011 , 60, 969-75		36
371	Treatment with insulin sensitizer metformin improves arterial properties, metabolic parameters, and liver function in patients with nonalcoholic fatty liver disease: a randomized, placebo-controlled trial. 2011 , 60, 1278-84		57
370	Treatment of atherogenic liver based on the pathogenesis of nonalcoholic fatty liver disease: a novel approach to reduce cardiovascular risk?. 2011 , 42, 337-53		29
369	Nonalcoholic fatty liver disease and the coronary artery disease. <i>Digestive Diseases and Sciences</i> , 2011 , 56, 35-45	4	56
368	Mechanisms linking nonalcoholic fatty liver disease with coronary artery disease. <i>Digestive Diseases and Sciences</i> , 2011 , 56, 3439-49	4	69
367	Atherogenic dyslipidemia and cardiovascular risk in children with nonalcoholic fatty liver disease. 2011 , 6, 305-314		28
366	Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study. 2011 , 343, d6891		253
365	Lipids in the wrong place: visceral fat and nonalcoholic steatohepatitis. 2011 , 34 Suppl 2, S367-70		29
364	Non-alcoholic fatty liver disease: what's new under the microscope?. 2011 , 60, 1152-8		23
363	Coronary artery disease and cardiovascular outcomes in patients with non-alcoholic fatty liver disease. 2011 , 60, 1721-7		205
362	Carotid intima-media thickness is increased not only in non-alcoholic fatty liver disease patients but also in alcoholic fatty liver patients. 2011 , 84, 149-55		12
361	Acetaminophen pharmacokinetics in children with nonalcoholic fatty liver disease. 2011 , 52, 198-202		39
360	The association between non-alcoholic hepatic steatosis and mean platelet volume in an obese Korean population. 2011 , 22, 442-6		28
359	Nonalcoholic fatty liver disease is associated with atherosclerosis in middle-aged and elderly Chinese. 2012 , 32, 2321-6		79

358	Hypercoagulation and thrombophilia in nonalcoholic fatty liver disease: mechanisms, human evidence, therapeutic implications, and preventive implications. 2012 , 32, 39-48	31
357	The association between nonalcoholic fatty liver disease, metabolic syndrome and arterial stiffness in nondiabetic, nonhypertensive individuals. 2012 , 123, 54-61	47
356	The pathogenesis of non-alcoholic fatty liver disease is closely related to the metabolic syndrome components. 2012 , 19, 311-321	1
355	Coronary artery disease and cardiovascular outcomes in patients with non-alcoholic fatty liver disease. 2012 , 2012, 53-56	
354	Editorial. Nonalcoholic fatty liver disease [how to manage a new cardiovascular risk factor?]. 2012 , 19, 225-228	
353	Coronary artery disease and cardiovascular outcomes in patients with non-alcoholic fatty liver disease. 2012 , 2012, 423-426	
352	Serum gamma-glutamyltransferase as a risk factor for general cardiovascular disease prediction in Koreans. 2012 , 60, 1199-203	5
351	Impaired myocardial perfusion reserve in patients with fatty liver disease assessed by quantitative myocardial perfusion magnetic resonance imaging. 2012 , 76, 2234-40	15
350	Coronary flow reserve evaluated by quantitative perfusion magnetic resonance imaging in patients with nonalcoholic fatty liver disease. 2012 , 76, 2094-5	
349	Phosphatidylcholine functional foods and nutraceuticals: A potential approach to prevent non-alcoholic fatty liver disease. 2012 , 114, 389-398	15
348	Patients transplanted for nonalcoholic steatohepatitis are at increased risk for postoperative cardiovascular events. <i>Hepatology</i> , 2012 , 56, 1741-50	11.2 154
347	NASH and atherosclerosis are two aspects of a shared disease: central role for macrophages. 2012 , 220, 287-93	66
346	Nonalcoholic fatty liver disease is associated with subclinical atherosclerosis independent of obesity and metabolic syndrome in Asian Indians. 2012 , 223, 507-11	72
345	Non-alcoholic fatty liver disease and cardiovascular disease. 2012 , 224, 324-5	10
344	Fatty liver, abdominal adipose tissue and atherosclerotic calcification in African Americans: the Jackson Heart Study. 2012 , 224, 521-5	60
343	Effects of increased systemic inflammation and central obesity on arterial stiffness in patients with nonalcoholic fatty liver disease. 2012 , 6, 253-60	18
342	Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population. 2012 , 10, 646-50	223
341	Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor?. 2012 , 33, 1190-200	312

340	Steatohepatitis and vascular thrombosis in apolipoprotein e deficient mice. 2012 , 129, e166-7	
339	The Framingham risk score and heart disease in nonalcoholic fatty liver disease. 2012 , 32, 945-50	112
338	Elevated hematocrit in nonalcoholic fatty liver disease: a potential cause for the increased risk of cardiovascular disease?. 2012 , 51, 59-68	14
337	Elevated asymmetric dimethylarginine in plasma: an early marker for endothelial dysfunction in non-alcoholic fatty liver disease?. 2012 , 96, 47-52	26
336	Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease. 2012 , 15, 665-74	395
335	Non-alcoholic fatty liver disease. 2012 , 4, 266-80	38
334	The cardiovascular link to nonalcoholic fatty liver disease: a critical analysis. 2012 , 16, 599-613	23
333	Increased risk of cardiovascular disease and chronic kidney disease in NAFLD. 2012 , 9, 372-81	90
332	Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. 2012 , 142, 711-725.e6	555
331	Fetuin-A and angiotensin in obesity and type 2 diabetes mellitus. 2012 , 42, 496-505	27
330	Non-alcoholic fatty liver disease and cardiovascular disease: epidemiological, clinical and pathophysiological evidences. 2012 , 7 Suppl 3, S291-6	24
329	Nonalcoholic fatty liver disease and atherosclerosis. 2012 , 7 Suppl 3, S297-305	34
328	Diabetes-induced alterations in the extracellular matrix and their impact on myocardial function. 2012 , 18, 22-34	34
327	Sinusoidal endothelial dysfunction precedes inflammation and fibrosis in a model of NAFLD. 2012 , 7, e32785	136
326	Metabolic syndrome and risk factors for non-alcoholic fatty liver disease. 2012 , 49, 89-96	123
325	Cholesterol and Inflammation at the Crossroads of Non-Alcoholic Fatty Liver Disease (NAFLD) and Atherogenesis. 2012 ,	1
324	Nonalcoholic fatty liver disease and cardiovascular disease: has the time come for cardiologists to be hepatologists?. 2012 , 2012, 483135	59
323	Relationship between Nonalcoholic Fatty Liver Disease and Carotid Artery Atherosclerosis Beyond Metabolic Disorders in Non-Diabetic Patients. 2012 , 20, 126-33	25

322 16 Leberfunktionsstörungen. **2012**,

321 Nonalcoholic fatty liver disease is associated with coronary artery calcification. *Hepatology*, **2012**, 56, 605-13 11.2 220

320 The relationship between arterial stiffness and nonalcoholic fatty liver disease. *Digestive Diseases and Sciences*, **2012**, 57, 196-203 4 59

319 Prevalence of hypothyroidism in nonalcoholic fatty liver disease. *Digestive Diseases and Sciences*, **2012**, 57, 528-34 4 119

318 Fatty liver index correlates with non-alcoholic fatty liver disease, but not with newly diagnosed coronary artery atherosclerotic disease in Chinese patients. **2013**, 13, 110 21

317 Hepatic notch signaling correlates with insulin resistance and nonalcoholic fatty liver disease. **2013**, 62, 4052-62 65

316 Non-alcoholic fatty liver disease and cardiovascular risk. **2013**, 167, 1109-17 64

315 Association of coronary artery calcification with hepatic steatosis in asymptomatic individuals. *Mayo Clinic Proceedings*, **2013**, 88, 1259-65 6.4 40

314 Nonalcoholic fatty liver disease and the metabolic syndrome: clinical implications and treatment. **2013**, 28, 40-51 46

313 Association of chitotriosidase genotype with the development of non-alcoholic fatty liver disease. *Hepatology Research*, **2013**, 43, 267-75 5.1 17

312 [Risk factors associated with non-alcoholic fatty liver disease: a case-control study]. **2013**, 141, 233-9 5

311 Carotid atherosclerosis or nonalcoholic fatty liver disease: which comes first?. **2013**, 231, 187-8 3

310 Plasma fetuin-A is associated with endothelial dysfunction and subclinical atherosclerosis in subjects with nonalcoholic fatty liver disease. **2013**, 78, 712-7 59

309 A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care?. **2013**, 230, 258-67 222

308 The clinical availability of non alcoholic fatty liver disease as an early predictor of the metabolic syndrome in Korean men: 5-year's prospective cohort study. **2013**, 227, 398-403 28

307 Assessment of endothelial function in patients with nonalcoholic fatty liver disease. **2013**, 43, 100-7 56

306 Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. **2013**, 10, 330-44 1022

305 Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. **2013**, 5, 1544-60 474

304	Omega-3 fatty acids for treatment of non-alcoholic fatty liver disease: design and rationale of randomized controlled trial. 2013 , 13, 85	48
303	Serum gamma glutamyl transferase and alanine transaminase concentrations predict endothelial dysfunction in patients with non-alcoholic steatohepatitis. 2013 , 118, 228-34	22
302	Nonalcoholic Fatty liver disease, diabetes mellitus and cardiovascular disease: newer data. 2013 , 2013, 450639	51
301	Diagnosis and management of nonalcoholic fatty liver disease and its hemostatic/thrombotic and vascular complications. 2013 , 39, 214-28	41
300	Independent Association between Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: A Systematic Review and Meta-Analysis. 2013 , 2013, 124958	55
299	Exercise training improves cutaneous microvascular function in nonalcoholic fatty liver disease. 2013 , 305, E50-8	38
298	Hepatic extracellular signal-regulated kinase 2 suppresses endoplasmic reticulum stress and protects from oxidative stress and endothelial dysfunction. 2013 , 2, e000361	19
297	Moderate oxidative stress and high antioxidative activity are associated with steatosis in Japanese males. 2013 , 6, 45-9	5
296	Ectopic fat: the true culprit linking obesity and cardiovascular disease?. 2013 , 110, 651-60	42
295	Evaluation of early atherosclerosis markers in patients with nonalcoholic fatty liver disease. 2013 , 25, 147-51	24
294	Evaluation of carotid artery stiffness in obese children using ultrasound radiofrequency data technology. 2013 , 32, 105-13	11
293	Cardiovascular and Systemic Risk in Nonalcoholic Fatty Liver Disease - Atherosclerosis as a Major Player in the Natural Course of NAFLD. 2013 , 19, 5177-5192	80
292	Relationship between retinal vascular caliber and coronary artery disease in patients with non-alcoholic fatty liver disease (NAFLD). 2013 , 10, 3409-23	10
291	Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification. 2013 , 19, 57-64	77
290	Cholesterol-induced non-alcoholic fatty liver disease and atherosclerosis aggravated by systemic inflammation. 2014 , 9, e97841	43
289	The effect of recombinant human growth hormone with or without rosiglitazone on hepatic fat content in HIV-1-infected individuals: a randomized clinical trial. 2016 , 21, 107-16	3
288	Xanthine oxidase activity is associated with risk factors for cardiovascular disease and inflammatory and oxidative status markers in metabolic syndrome: effects of a single exercise session. 2014 , 2014, 587083	41
287	Clinical significance of non-alcoholic fatty liver disease as a risk factor for prehypertension. 2014 , 29, 973-9	17

286	Nonalcoholic fatty liver disease and vascular disease: state-of-the-art. 2014 , 20, 13306-24	135
285	Nonalcoholic fatty liver disease (NAFLD) - a new factor that interplays between inflammation, malnutrition, and atherosclerosis in elderly hemodialysis patients. 2014 , 9, 1295-303	21
284	The Levels of Soluble Intercellular Adhesion Molecule, Vascular Adhesion Molecule and Se-Selectin Levels in Patients with Non-Alcoholic Fatty Liver Disease. 2014 , 05,	1
283	Clinical association between non-alcoholic fatty liver disease and the development of hypertension. 2014 , 29, 1926-31	68
282	Epidemiology of Nonalcoholic Fatty Liver Disease (NAFLD). 2014 , 357-372	1
281	Exercise training reverses endothelial dysfunction in nonalcoholic fatty liver disease. 2014 , 307, H1298-306	68
280	Association between non-alcoholic fatty liver disease and arterial stiffness in the non-obese, non-hypertensive, and non-diabetic young and middle-aged Chinese population. 2014 , 15, 879-87	22
279	Non-alcoholic fatty liver disease, metabolic syndrome and subclinical cardiovascular changes in the general population. 2014 , 100, 938-43	68
278	Endothelial dysfunction in patients with non-alcoholic steatohepatitis. 2014 , 119, 290-1	
277	From NAFLD to Cardiovascular Disease. Is it (Still) the Metabolic Syndrome?. 2014 , 87, 80-6	2
276	Liver status in congenital, untreated, isolated GH deficiency. 2014 , 3, 132-7	6
275	Nonalcoholic fatty liver disease (NAFLD)--is it a new marker of hyporesponsiveness to recombinant human erythropoietin in patients that are on chronic hemodialysis?. 2014 , 83, 798-801	3
274	Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease. 2014 , 40, 1209-22	196
273	A comparison of cardiovascular risk indices in patients with polycystic ovary syndrome with and without coexisting nonalcoholic fatty liver disease. 2014 , 80, 843-9	16
272	The relation between carotid intima media thickness and serum osteoprotegerin levels in nonalcoholic fatty liver disease. 2014 , 12, 283-9	7
271	Changes in the levels of endothelium-derived coagulation parameters in nonalcoholic fatty liver disease. 2014 , 25, 151-5	9
270	Nonalcoholic fatty liver disease (NAFLD) and cardiovascular risk in renal transplant recipients. 2014 , 39, 308-14	18
269	Non-alcoholic fatty liver disease proven by transient elastography in hemodialysis patients: is it a new risk factor for adverse cardiovascular events?. 2014 , 37, 259-65	14

268	The interactions of nonalcoholic fatty liver disease and cardiovascular diseases. 2014 , 18, 233-48	15
267	The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease. 2014 , 12, 2085-91.e1	186
266	Extrahepatic complications of nonalcoholic fatty liver disease. <i>Hepatology</i> , 2014 , 59, 1174-97	11.2 350
265	Epigallocatechin-3-gallate restores the Bcl-2 expression in liver of young rats challenged with hypercholesterolemia but not in aged rats: an insight into its disparity of efficacy on advancing age. 2014 , 5, 916-26	3
264	Arterial stiffness in patients with non-alcoholic fatty liver disease is related to fibrosis stage and epicardial adipose tissue thickness. 2014 , 237, 490-3	54
263	Almonds inhibit dyslipidemia and vascular dysfunction in rats through multiple pathways. 2014 , 144, 1768-74	13
262	Non-high-density lipoprotein cholesterol (non-HDL-C) levels in children with nonalcoholic fatty liver disease (NAFLD). 2014 , 3, 407	17
261	Nonalcoholic fatty liver disease (NAFLD) proven by transient elastography in patients with coronary heart disease. 2014 , 126, 474-9	11
260	NAFLD and Cardiovascular Disease: Can the Real Association Be Determined?. 2014 , 13, 130-141	4
259	Non Alcoholic Fatty Liver: Should We Care?. 2014 , 8, 1	1
258	Diastolic dysfunction and cardiovascular risk in old subjects: possible association with NAFLD?. 2014 , 58, 188-95	8
257	Procoagulant imbalance in patients with non-alcoholic fatty liver disease. 2014 , 61, 148-54	113
256	Nonalcoholic Fatty liver disease in renal transplant recipients proven by transient elastography. 2014 , 46, 1347-52	10
255	Associations between nonalcoholic fatty liver disease and subclinical atherosclerosis in middle-aged adults: the Coronary Artery Risk Development in Young Adults Study. 2014 , 235, 599-605	106
254	Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease. 2014 , 20, 1724-45	160
253	Longitudinal assessment of high blood pressure in children with nonalcoholic fatty liver disease. 2014 , 9, e112569	59
252	A potential link between endothelial function, cardiovascular risk, and metabolic syndrome in patients with Non-alcoholic fatty liver disease. 2014 , 6, 109	8
251	The Double-Edged Sword of Hepatic Iron Metabolism in Health and Diseases. 2014 , 212-229	

250	Nonalcoholic fatty liver disease, nocturnal hypoxia, and endothelial function in patients with sleep apnea. 2014 , 145, 525-533		55
249	Left ventricular dysfunction in obese children and adolescents with nonalcoholic fatty liver disease. <i>Hepatology</i> , 2014 , 59, 461-70	11.2	77
248	Research advances in the relationship between nonalcoholic fatty liver disease and atherosclerosis. 2015 , 14, 158		33
247	Nonalcoholic fatty liver disease and carotid artery atherosclerosis in children and adults: a meta-analysis. 2015 , 27, 1237-48		50
246	Impact of renal impairment on cardiovascular disease mortality after liver transplantation for nonalcoholic steatohepatitis cirrhosis. 2015 , 35, 2575-83		44
245	Higher association of coronary artery calcification with non-alcoholic fatty liver disease than with abdominal obesity in middle-aged Korean men: the Kangbuk Samsung Health Study. <i>Cardiovascular Diabetology</i> , 2015 , 14, 88	8.7	28
244	Nonalcoholic Steatohepatitis Score is an Independent Predictor of Right Ventricular Dysfunction in Patients with Nonalcoholic Fatty Liver Disease. 2015 , 33, 294-9		16
243	Relationship between non-alcoholic fatty liver disease and MIA syndrome. 2015 , 19, 472-81		3
242	Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: A population-based study. <i>Hepatology</i> , 2015 , 62, 773-83	11.2	157
241	Diagnostic accuracy of a noninvasive hepatic ultrasound score for non-alcoholic fatty liver disease (NAFLD) in the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). 2015 , 133, 115-24		15
240	Nonalcoholic Fatty Liver Disease Is Associated with the Presence and Morphology of Subclinical Coronary Atherosclerosis. 2015 , 56, 1288-95		8
239	Vascular and hepatic impact of short-term intermittent hypoxia in a mouse model of metabolic syndrome. 2015 , 10, e0124637		8
238	Nonalcoholic Hepatic Steatosis Is a Strong Predictor of High-Risk Coronary-Artery Plaques as Determined by Multidetector CT. 2015 , 10, e0131138		30
237	Association of Nonalcoholic Fatty Liver Disease with Subclinical Cardiovascular Changes: A Systematic Review and Meta-Analysis. 2015 , 2015, 213737		53
236	Oxidative stress: New insights on the association of non-alcoholic fatty liver disease and atherosclerosis. 2015 , 7, 1325-36		116
235	Use of Ursodeoxycholic Acid on Post-menopausal Obesity, Hepatic steatosis and Plasma Profile as an Alternative Treatment for Hormone Replacement Therapy. 2015 , 58, 898-904		
234	The association of nonalcoholic fatty liver disease with central and peripheral blood pressure in adolescence: findings from a cross-sectional study. 2015 , 33, 546-52; discussion 553		9
233	Hepatokines as a Link between Obesity and Cardiovascular Diseases. 2015 , 39, 10-5		60

232	Not all fats are created equal: adipose vs. ectopic fat, implication in cardiometabolic diseases. 2015 , 22, 7-18	31
231	High Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels. 2015 , 100, 2231-8	304
230	Microcystin-LR altered mRNA and protein expression of endoplasmic reticulum stress signaling molecules related to hepatic lipid metabolism abnormalities in mice. 2015 , 40, 114-21	15
229	Association between nonalcoholic fatty liver disease and coronary artery calcification in postmenopausal women. 2015 , 22, 1323-7	24
228	Impact of Nonalcoholic Fatty Liver Disease on Myocardial Perfusion in Nondiabetic Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction. 2015 , 116, 1810-4	24
227	Non-alcoholic fatty liver disease is associated with progression of arterial stiffness. 2015 , 25, 218-23	32
226	Fetuin-A negatively correlates with liver and vascular fibrosis in nonalcoholic fatty liver disease subjects. 2015 , 35, 925-35	42
225	Impact of high dose n-3 polyunsaturated fatty acid treatment on measures of microvascular function and vibration perception in non-alcoholic fatty liver disease: results from the randomised WELCOME trial. 2015 , 58, 1916-25	16
224	Relation of nonalcoholic fatty liver disease and Framingham Risk Score to flow-mediated dilation in patients with cardiometabolic risk factors. 2015 , 115, 1402-6	20
223	Usefulness of liver test and controlled attenuation parameter in detection of nonalcoholic fatty liver disease in patients with chronic renal failure and coronary heart disease. 2015 , 127, 451-8	12
222	Prevalence of hypothyroidism in nonalcoholic fatty liver disease in patients attending a tertiary hospital in western India. 2015 , 34, 169-73	21
221	Association between liver fibrosis and coronary heart disease risk in patients with nonalcoholic fatty liver disease. 2015 , 27, 298-304	16
220	Nonalcoholic fatty liver disease as a potential risk factor of cardiovascular disease. 2015 , 27, 193-9	40
219	Induction of spontaneous neo-angiogenesis and tube formation in human endometrial stem cells by bioglass. 2015 , 9, 94-98	7
218	Non-Alcoholic Fatty Liver Disease (NAFLD): A New Cardiovascular Risk Factor. 2015 , 22, 209-216	
217	Nonalcoholic fatty liver disease and vascular function: cross-sectional analysis in the Framingham heart study. 2015 , 35, 1284-91	53
216	Clinical features of fatty liver in nonobese Japanese without regular alcohol intake. 2015 , 6, 60-65	1
215	Comparison of magnetic resonance spectroscopy, proton density fat fraction and histological analysis in the quantification of liver steatosis in children and adolescents. 2016 , 22, 8812-8819	54

214	Nonalcoholic fatty liver disease - A multisystem disease?. 2016 , 22, 9488-9505		103
213	Risk stratification and preoperative evaluation of the patient with known or suspected liver disease. 2016 , 7, 101-105		5
212	Steatosis Grade is the Most Important Risk Factor for Development of Endothelial Dysfunction in NAFLD. 2016 , 95, e3280		13
211	Long-term clinical outcomes after fatty liver screening in patients undergoing coronary angiogram: A prospective cohort study. <i>Hepatology</i> , 2016 , 63, 754-63	11.2	68
210	Novel Pharmacotherapy Options for NASH. <i>Digestive Diseases and Sciences</i> , 2016 , 61, 1398-405	4	27
209	Association of non-alcoholic fatty liver disease with impaired endothelial function by flow-mediated dilation: A meta-analysis. <i>Hepatology Research</i> , 2016 , 46, E165-73	5.1	14
208	Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease. 2016 , 15, 75-85		71
207	Non-alcoholic fatty liver disease fibrosis score and preclinical vascular damage in morbidly obese patients. 2016 , 48, 904-8		4
206	Fatty liver is an independent predictor of early carotid atherosclerosis. 2016 , 65, 95-102		67
205	Venous thromboembolism with chronic liver disease. 2016 , 168-170		
204	De novo lipogenesis in the liver in health and disease: more than just a shunting yard for glucose. 2016 , 91, 452-68		207
203	Autophagy Networks in Cardiovascular Diseases. 2016 , 297-322		
202	Autophagy Networks in Inflammation. 2016 ,		1
201	Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: A systematic review and meta-analysis. 2016 , 6, 33386		143
200	Non-alcoholic fatty liver disease and cardiovascular risk: Pathophysiological mechanisms and implications. 2016 , 65, 425-43		239
199	Nonalcoholic Fatty Liver Disease Is Associated With Coronary Artery Calcification Development: A Longitudinal Study. 2016 , 101, 3134-43		35
198	Persistent Nonalcoholic Fatty Liver Disease Increases Risk for Carotid Atherosclerosis. 2016 , 151, 481-488.e1		71
197	The Liver in Systemic Diseases. 2016 ,		1

196	Hepatic insulin resistance in NAFLD: relationship with markers of atherosclerosis and metabolic syndrome components. 2016 , 53, 449-59	11
195	Comparison of the Phenotype and Approach to Pediatric vs Adult Patients With Nonalcoholic Fatty Liver Disease. 2016 , 150, 1798-810	84
194	Hepatic Steatosis and Insulin Resistance, But Not Steatohepatitis, Promote Atherogenic Dyslipidemia in NAFLD. 2016 , 101, 644-52	95
193	Nonalcoholic fatty liver disease is associated with cognitive function in adults. 2016 , 86, 1136-42	79
192	Non-alcoholic fatty liver disease and liver transplantation. 2016 , 65, 1208-23	35
191	Hepatosteatosis and carotid intima-media thickness in patients with myocardial infarction. 2016 , 43, 77-82	6
190	mTORC1-independent Raptor prevents hepatic steatosis by stabilizing PHLPP2. 2016 , 7, 10255	38
189	Nonalcoholic Fatty Liver Disease (NAFLD)-A New Cardiovascular Risk Factor in Peritoneal Dialysis Patients. 2016 , 36, 427-32	17
188	Race/ethnic and sex disparities in the non-alcoholic fatty liver disease-abdominal aortic calcification association: The Multi-Ethnic Study of Atherosclerosis. 2017 , 258, 89-96	11
187	"Non alcoholic fatty liver disease and eNOS dysfunction in humans". 2017 , 17, 35	32
186	Diagnosis of fatty liver by computed tomography coronary artery calcium score. 2017 , 34, 937-938	5
185	Nonalcoholic fatty liver disease, association with cardiovascular disease and treatment. (i). Nonalcoholic fatty liver disease and its association with cardiovascular disease. 2017 , 29, 141-148	4
184	Role of folate in nonalcoholic fatty liver disease. 2017 , 95, 1141-1148	34
183	Serum vascular cell adhesion molecule-1 predicts significant liver fibrosis in non-alcoholic fatty liver disease. 2017 , 41, 1207-1213	28
182	Cardiovascular mortality among liver transplant recipients with nonalcoholic steatohepatitis in the United States-a retrospective study. 2017 , 30, 1051-1060	7
181	Nonalcoholic Fatty Liver Disease in Children: Hepatic and Extrahepatic Complications. 2017 , 64, 659-675	27
180	Diabetic status and grade of nonalcoholic fatty liver disease are associated with lower baroreceptor sensitivity in patients with nonalcoholic fatty liver disease. 2017 , 29, 956-961	7
179	Associations between arterial structure and function and serum levels of liver enzymes in obese adolescents. 2017 , 53, 691-697	2

178	Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. 2017 , 66, 1138-1153	508
177	Non-alcoholic fatty liver disease and progression of coronary artery calcium score: a retrospective cohort study. 2017 , 66, 323-329	85
176	Non-alcoholic fatty liver disease, to struggle with the strangle: Oxygen availability in fatty livers. 2017 , 13, 386-392	19
175	Nonalcoholic fatty liver and the severity of acute pancreatitis. 2017 , 38, 73-78	12
174	Non-alcoholic fatty liver disease (NAFLD) and 10-year risk of cardiovascular diseases. 2017 , 41, 31-38	54
173	Nonalcoholic fatty liver disease, association with cardiovascular disease and treatment. (I). Nonalcoholic fatty liver disease and its association with cardiovascular disease. 2017 , 29, 141-148	6
172	Association between vascular inflammation and non-alcoholic fatty liver disease: Analysis by F-fluorodeoxyglucose positron emission tomography. 2017 , 67, 72-79	19
171	Nonalcoholic Fatty Liver Disease. 2017 , 867-908	1
170	Impact of diabetes mellitus and chronic liver disease on the incidence of dementia and all-cause mortality among patients with dementia. 2017 , 96, e8753	8
169	The Association between Non-Alcoholic Fatty Liver Disease and Cardiovascular Risk in Children. 2017 , 4,	6
168	NAFLD and Atherosclerosis Are Prevented by a Natural Dietary Supplement Containing Curcumin, Silymarin, Guggul, Chlorogenic Acid and Inulin in Mice Fed a High-Fat Diet. 2017 , 9,	39
167	Non-Alcoholic Fatty Liver Disease: The Emerging Burden in Cardiometabolic and Renal Diseases. 2017 , 41, 430-437	37
166	Non-alcoholic fatty liver disease and cardiovascular risk. 2017 , 8, 51-58	79
165	Hepatic microvascular dysfunction and increased advanced glycation end products are components of non-alcoholic fatty liver disease. 2017 , 12, e0179654	27
164	Non-alcoholic fatty liver disease as a risk factor for female sexual dysfunction in premenopausal women. 2017 , 12, e0182708	2
163	[Cardiovascular Risk in Patients with Non-alcoholic Fatty Liver Disease]. 2017 , 69, 333-340	
162	Correlation between PPAR- β methylation level in peripheral blood and atherosclerosis of NAFLD patients with DM. 2018 , 15, 2727-2730	3
161	Nonalcoholic fatty liver disease contributes to subclinical atherosclerosis: A systematic review and meta-analysis. 2018 , 2, 376-392	53

160	Synergistic increase in cardiovascular risk in diabetes mellitus with nonalcoholic fatty liver disease: a meta-analysis. 2018 , 30, 631-636	37
159	Effects of dark chocolate on endothelial function in patients with non-alcoholic steatohepatitis. 2017 , 28, 143-149	25
158	Steato-Score: Non-Invasive Quantitative Assessment of Liver Fat by Ultrasound Imaging. 2018 , 44, 1585-1596	8
157	Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis in Liver Transplantation. 2018 , 22, 213-227	14
156	Is there a J-shaped relationship between the fatty liver index and risk of microalbuminuria in the general population?. 2018 , 481, 231-237	3
155	NAFLD/NASH in patients with type 2 diabetes and related treatment options. 2018 , 41, 509-521	32
154	Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence?. 2018 , 68, 335-352	298
153	Swimming, but not vitamin E, ameliorates prothrombotic state and hypofibrinolysis in a rat model of nonalcoholic fatty liver disease. 2018 , 29, 61-71	6
152	Life-style-induced metabolic derangement and epigenetic changes promote diabetes and oxidative stress leading to NASH and atherosclerosis severity. 2018 , 17, 381-391	9
151	Reactive hyperemia index can screen endothelial dysfunction in obese subjects with non-alcoholic fatty liver disease. 2018 , 2, 39-44	
150	Non-alcoholic fatty liver disease and cardiovascular risk: an update. 2018 , 12, 1175-1177	7
149	Association of non-alcoholic fatty liver disease with cardiovascular disease and subclinical atherosclerosis. 2018 , 14, 1233-1244	26
148	Nonalcoholic steatohepatitis, obesity, and cardiac dysfunction. 2018 , 25, 315-320	5
147	Association between Thyroid-Stimulating Hormone Levels and Non-Alcoholic Fatty Liver Disease Is Not Independent from Metabolic Syndrome Criteria. 2018 , 7, 302-307	10
146	Non-alcoholic fatty liver disease: Relationship with cardiovascular risk markers and clinical endpoints. 2018 , 144, 144-152	14
145	A High-Fat and High-Cholesterol Diet Induces Cardiac Fibrosis, Vascular Endothelial, and Left Ventricular Diastolic Dysfunction in SHRSP5/Dmcr Rats. 2018 , 25, 439-453	22
144	Bushenkangshuai Tablet Reduces Atherosclerotic Lesion by Improving Blood Lipids Metabolism and Inhibiting Inflammatory Response via TLR4 and NF-B Signaling Pathway. 2018 , 2018, 1758383	2
143	Cognitive Changes and Brain Volume Reduction in Patients with Nonalcoholic Fatty Liver Disease. 2018 , 2018, 9638797	19

142	Association between nonalcoholic fatty liver disease and subclinical atherosclerosis: a cross-sectional study on population over 40 years old. 2018 , 18, 147	16
141	Reactive hyperemia index (RHI) and cognitive performance indexes are associated with histologic markers of liver disease in subjects with non-alcoholic fatty liver disease (NAFLD): a case control study. <i>Cardiovascular Diabetology</i> , 2018 , 17, 28	8,7 22
140	Oral Anticoagulation in Patients With Liver Disease. 2018 , 71, 2162-2175	83
139	The impact of non-alcoholic fatty liver disease and metabolic syndrome on the progression of coronary artery calcification. 2018 , 8, 12004	13
138	C-type natriuretic peptide (CNP) in endothelial cells attenuates hepatic fibrosis and inflammation in non-alcoholic steatohepatitis. 2018 , 209, 349-356	7
137	A Long-term Estrogen Deficiency in Ovariectomized Mice is Associated with Disturbances in Fatty Acid Oxidation and Oxidative Stress. 2018 , 40, 251-259	10
136	Relationship between endothelium-dependent vasodilation and fat distribution using the new "imimomics" image analysis technique. 2019 , 29, 1077-1086	2
135	Porphyromonas gingivalis-derived lipopolysaccharide causes excessive hepatic lipid accumulation via activating NF- κ B and JNK signaling pathways. 2019 , 25, 1789-1797	14
134	HDL flux is higher in patients with nonalcoholic fatty liver disease. 2019 , 317, E852-E862	11
133	Hepatic fat: Pathogenic trigger or passenger?. 2019 , 71, 249-251	
132	Non-alcoholic fatty liver disease and neurological defects. 2019 , 18, 563-570	7
131	Probing the Liver-Heart Axis. 2019 , 291, 338-339	1
130	Screening of Cardiovascular Disease in Nonalcoholic Fatty Liver Disease: Whom and How?. 2019 , 9, 506-514	23
129	ADAMTS5 deficiency in mice does not affect cardiac function. 2019 , 43, 593-604	5
128	Nonalcoholic Fatty Liver Disease and the Heart: JACC State-of-the-Art Review. 2019 , 73, 948-963	135
127	New insights into the association between non-alcoholic fatty liver disease and atherosclerosis. 2019 , 7, S300	6
126	Impact of Non-Alcoholic Fatty Liver Disease on Cardiovascular Outcomes in Patients With Stable Coronary Artery Disease: A Matched Case-Control Study. 2019 , 10, e00011	12
125	An AGTR1 Variant Worsens Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome. 2019 , 114, 556-559	3

124	Substance P Promotes Liver Sinusoidal Endothelium-Mediated Hepatic Regeneration by NO/HGF Regulation. 2019 , 39, 147-154		3
123	Adult Non-alcoholic Fatty Liver Disease (NAFLD). 2019 , 23-46		
122	The Interplay Between Nonalcoholic Fatty Liver Disease and Atherosclerotic Heart Disease. <i>Hepatology</i> , 2019 , 69, 1372-1374	11.2	9
121	Nonalcoholic Fatty Liver Disease, Male Sexual Dysfunction, and Infertility: Common Links, Common Problems. 2020 , 8, 274-285		14
120	Hepatocyte-derived extracellular vesicles promote endothelial inflammation and atherogenesis via microRNA-1. 2020 , 72, 156-166		67
119	The Critically Ill Cirrhotic Patient. 2020 ,		
118	The Efficacy of Vitamin D Supplementation against Nonalcoholic Fatty Liver Disease: A Meta-Analysis. 2020 , 17, 467-485		5
117	Extra-Hepatic Manifestations of Nonalcoholic Fatty Liver Disease: A Review. 2020 , 10, 81-87		14
116	Non-alcoholic fatty liver disease and the incidence of myocardial infarction: A cohort study. 2020 , 35, 833-839		35
115	Pyridoxamine improves metabolic and microcirculatory complications associated with nonalcoholic fatty liver disease. 2020 , 27, e12603		7
114	Non-Alcoholic Fatty Liver Disease. 2020 ,		1
113	NAFLD and cardiovascular diseases: a clinical review. 2021 , 110, 921-937		77
112	Endothelial Dysfunction, a Marker of Atherosclerosis, Is Independent of Metabolic Syndrome in NAFLD Patients. 2020 , 2020, 1825142		3
111	Cerebral hemodynamics in the non-alcoholic fatty liver. 2020 , 19, 668-673		1
110	Association between noninvasive assessment of liver fibrosis and coronary artery calcification progression in patients with nonalcoholic fatty liver disease. 2020 , 10, 18323		6
109	Epidemiology of moderate-to-severe psoriasis: a comparison between psoriasis patients treated with biological agents, conventional systemic drugs and topical agents. 2020 , 1-14		2
108	Genetic Variants Associated with Non-Alcoholic Fatty Liver Disease Do Not Associate with Measures of Sub-Clinical Atherosclerosis: Results from the IMPROVE Study. 2020 , 11,		1
107	Non-alcoholic fatty liver disease is associated with cardiovascular disease in subjects with different glucose tolerance. 2020 , 36, e3333		9

106	Endothelial dysfunction in nonalcoholic steatohepatitis with low cardiac disease risk. 2020 , 10, 8825	4
105	The risk of pregnancy-associated hypertension in women with nonalcoholic fatty liver disease. 2020 , 40, 2417-2426	4
104	Nonalcoholic Fatty Liver Disease. 2020 , 1	2
103	Nonalcoholic fatty liver disease and cardiovascular disease phenotypes. 2020 , 8, 2050312120933804	3
102	Association between high dose catecholamine support and liver dysfunction following cardiac surgery. 2020 , 35, 1228-1236	3
101	Nonalcoholic Fatty Liver Disease and Sarcopenia Are Independently Associated With Cardiovascular Risk. 2020 , 115, 584-595	24
100	Aspirin Improves Nonalcoholic Fatty Liver Disease and Atherosclerosis through Regulation of the PPAR-AMPK-PGC-1 Pathway in Dyslipidemic Conditions. 2020 , 2020, 7806860	7
99	High Prevalence of Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels. 2014 , 100,	13
98	Non-invasive markers of liver fibrosis and outcome in large vessel occlusion stroke. 2021 , 14, 17562864211037339	3
97	NAFLD and Cardiovascular Diseases: Epidemiological, Mechanistic and Therapeutic Considerations. 2021 , 10,	11
96	Non-Alcoholic Fatty Liver Disease: From Pathogenesis to Clinical Impact. 2021 , 9, 135	14
95	Impact of liver fibrosis score on prognosis in patients with previous myocardial infarction: A prospective cohort study. 2021 , 41, 1294-1304	3
94	Non-alcoholic fatty liver disease and heart failure with preserved ejection fraction: from pathophysiology to practical issues. 2021 , 8, 789-798	4
93	The association of the steatosis severity, NAFLD fibrosis score and FIB-4 index with atherogenic dyslipidaemia in adult patients with NAFLD: A cross-sectional study. 2021 , 75, e14131	4
92	Interplay between Heart Disease and Metabolic Steatosis: A Contemporary Perspective. 2021 , 10,	2
91	Targeting Liver Sinusoidal Endothelial Cells: An Attractive Therapeutic Strategy to Control Inflammation in Nonalcoholic Fatty Liver Disease. 2021 , 12, 655557	5
90	1-year outcomes for lung transplantation recipients with non-alcoholic fatty liver disease. 2021 , 7,	
89	Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: Overlapping Mechanisms. 2021 , 41, 235-247	1

88	Endothelial Progenitor Cells Dysfunctions and Cardiometabolic Disorders: From Mechanisms to Therapeutic Approaches. 2021 , 22,	4
87	Low testosterone and cardiometabolic risks in a real-world study of US male firefighters. 2021 , 11, 14189	
86	The progression and regression of metabolic dysfunction-associated fatty liver disease are associated with the development of subclinical atherosclerosis: A prospective analysis. 2021 , 120, 154779	3
85	Management of Patients With Non-alcoholic Steatohepatitis Undergoing Liver Transplantation: Considerations for the Anesthesiologist. 2021 ,	1
84	Extent and features of liver steatosis in vitro pave the way to endothelial dysfunction without physical cell-to-cell contact. 2021 , 31, 3522-3532	0
83	Liver fibrosis is associated with carotid atherosclerosis in patients with liver biopsy-proven nonalcoholic fatty liver disease. 2021 , 11, 15938	5
82	Clinical perspectives, assessment, and mechanisms of metabolic-associated fatty liver disease in patients with COVID-19. 2021 , 27, 5502-5519	
81	Hepatic Interactions in Atherosclerotic Heart Disease. 2021 ,	0
80	Coronary CT Angiography in Asymptomatic Adults with Hepatic Steatosis. 2021 , 301, 593-601	
79	Cerebrovascular alterations in NAFLD: Is it increasing our risk of Alzheimer's disease?. 2021 , 114387	2
78	Longitudinal Association of Non-Alcoholic Fatty Liver Disease With Changes in Myocardial Structure and Function: The CARDIA Study. 2020 , 9, e014279	35
77	The hepatokine Tsukushi is released in response to NAFLD and impacts cholesterol homeostasis. 2019 , 4,	22
76	White and Brown Adipose Tissue Development. 2014 , 237-246	1
75	Decreased circulating endothelial progenitor cell levels and function in patients with nonalcoholic fatty liver disease. 2012 , 7, e31799	33
74	The endothelial dysfunction blocker CU06-1004 ameliorates choline-deficient L-amino acid diet-induced non-alcoholic steatohepatitis in mice. 2020 , 15, e0243497	2
73	Comorbidities and Metabolic Derangement of NAFLD. 2015 , 5, 7-13	40
72	The Role of Non-alcoholic Fatty Liver Disease in Cardiovascular Disease. 2014 , 9, 10-15	6
71	Non-Alcoholic Fatty Liver Disease and Cardiovascular Risk. 2008 , 2, 509-518	1

70	[Non-alcoholic fatty liver disease and cardiovascular risk]. 2008 , 149, 1299-305	3
69	Diabetes and impaired glucose regulation in first-degree relatives of patients with type 2 diabetes in isfahan, iran: prevalence and risk factors. 2007 , 4, 169-76	45
68	First-degree relatives of patients with type 2 diabetes mellitus and risk of non-alcoholic Fatty liver disease. 2007 , 4, 236-41	10
67	Non-Alcoholic Fatty Liver Disease and Vascular Disease. 2021 , 19, 269-279	6
66	[Nonalcoholic fatty liver disease as a risk factor of cardiovascular disease]. 2008 , 14, 1-3	2
65	[Nonalcoholic fatty liver disease as a risk factor of cardiovascular disease: relation of non-alcoholic fatty liver disease to carotid atherosclerosis]. 2008 , 14, 77-88	33
64	Carotid lesions in outpatients with nonalcoholic fatty liver disease. 2009 , 15, 4770-4	26
63	Fatty liver, carotid disease and gallstones: a study of age-related associations. 2006 , 12, 5826-33	46
62	Pediatric nonalcoholic fatty liver disease, metabolic syndrome and cardiovascular risk. 2011 , 17, 3082-91	89
61	Nonalcoholic fatty liver disease: updates in noninvasive diagnosis and correlation with cardiovascular disease. 2014 , 20, 7718-29	24
60	Nonalcoholic fatty liver disease and the heart in children and adolescents. 2014 , 20, 9055-71	24
59	Intrahepatic vascular changes in non-alcoholic fatty liver disease: Potential role of insulin-resistance and endothelial dysfunction. 2017 , 23, 6777-6787	19
58	Non-alcoholic steatohepatitis and the risk of myocardial infarction: A population-based national study. 2020 , 12, 378-388	4
57	Composite prognostic models across the non-alcoholic fatty liver disease spectrum: Clinical application in developing countries. 2015 , 7, 1192-208	7
56	Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease. 2020 , 14, 168-178	28
55	Nutraceutical and Functional Food Application to Nonalcoholic Steatohepatitis. 2006 , 485-502	
54	NAFLD and Cardiovascular Risk Factors: Implications for Vascular Disease. 71-83	
53	EVALUATION OF CARDIOVASCULAR RISK BY CAROTID INTIMA MEDIA THICKNESS IN NON ALCOHOLIC FATTY LIVER DISEASE. 2013 , 2, 8110-8114	

52	Heart Disease and the Liver: Interactions Between the Heart and the Liver. 2016 , 179-202	
51	Critical Evaluation for Alternative Causes of Drug Induced and Herbal Induced (DILI/HILI) Hepatotoxicity. 2016 , 08, 800-804	
50	Connection between nonalcoholic fatty liver disease and arterial hypertension. 2017 , 12, 86-86	
49	QUALITY OF LIFE IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE WITH ENDOTHELIAL DYSFUNCTION. 2018 , 1.1, 152	
48	Future of pharmacological treatment of non-alcoholic steatohepatitis in terms of key pathophysiological mechanisms. 2018 , 64, 735-741	
47	Anticoagulation in the Hospitalized Patient with Decompensated Cirrhosis: Management of a Delicate Balance. 2020 , 219-236	
46	The association between coronary artery disease and nonalcoholic fatty liver disease and noninvasive imaging methods. 2019 , 16, em165	
45	Semi-quantitative ultrasound assessment of nonalcoholic fatty liver disease highlightens early subclinical atherosclerotic vascular damage: From risk factors to vascular damage. 2020 ,	0
44	NAFLD as a continuous driver in the whole spectrum of vascular disease. 2021 , 163, 118-132	1
43	NAFLD and Cardiovascular and Cardiac Disease: Clinical Implications. 2020 , 169-197	
42	Pharmacological Options for NASH. 2020 , 309-327	
41	Non-alcoholic steatohepatitis and the risk of myocardial infarction: A population-based national study. 2020 , 12, 379-389	
40	Non alcoholic fatty liver disease and metabolic syndrome. 2009 , 13, 9-19	295
39	Effect of non-alcoholic fatty liver disease on carotid artery intima-media thickness as a risk factor for atherosclerosis. 2014 , 7, 55-62	12
38	Cardiovascular disorders in the context of non-alcoholic Fatty liver disease: a literature review. 2014 , 9, 1-8	3
37	Cardiovascular dysfunction in patients with liver cirrhosis. 2015 , 28, 31-40	62
36	Association between nonalcoholic fatty liver disease and carotid atherosclerosis: a meta-analysis. 2015 , 8, 7673-8	18
35	Liver fat content is negatively associated with atherosclerotic carotid plaque in type 2 diabetic patients. 2015 , 5, 792-8	7

34	Prevalence of non-alcoholic fatty liver disease in patients with coronary artery disease. 2016 , 12, 201-205	6	
33	Ramipril significantly attenuates the development of non-alcoholic steatohepatitis in hyperlipidaemic rabbits. 2019 , 9, 8-17	3	
32	Association of non-alcoholic fatty liver disease with coronary artery calcification progression: a systematic review and meta-analysis. 2021 , 16, 196-206	0	
31	Coagulation and Endothelial Dysfunction Associated with NAFLD: Current Status and Therapeutic Implications.. 2022 , 10, 339-355	3	
30	Subclinical hepatic fibrosis is associated with coronary microvascular dysfunction by myocardial perfusion reserve index: a retrospective cohort study.. 2022 , 1	0	
29	Astragaloside IV Relieves Atherosclerosis and Hepatic Steatosis MAPK/NF-B Signaling Pathway in LDLR Mice.. 2022 , 13, 828161	0	
28	Gender-Based Association of Coronary Artery Calcification and Framingham Risk Score With Non-alcoholic Fatty Liver Disease and Abdominal Obesity in Taiwanese Adults, a Cross-Sectional Study.. 2022 , 9, 803967	0	
27	Fibrotic Burden Determines Cardiovascular Risk among Subjects with Metabolic Dysfunction-Associated Fatty Liver Disease.. 2022 ,	0	
26	Novel Coconut Vinegar Attenuates Hepatic and Vascular Oxidative Stress in Rats Fed a High-Cholesterol Diet.. 2022 , 9, 835278	0	
25	Towards harnessing the value of organokine crosstalk to predict the risk for cardiovascular disease in non-alcoholic fatty liver disease.. 2022 , 130, 155179	0	
24	Non-alcoholic fatty liver disease as an independent factor of cardiometabolic risk of cardiovascular diseases. 2021 , 22-34	0	
23	Risk of cardiovascular events in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis.. 2021 ,	4	
22	Association of non-alcoholic fatty liver disease with coronary artery calcification progression: a systematic review and meta-analysis. 2021 , 16, 196-206	0	
21	Endothelial Dysfunction in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. <i>Life</i> , 2022 , 12, 718	3	0
20	High fatty liver index is an independent predictor of ischemic heart disease during a 10-year period in a Japanese population.. <i>Hepatology Research</i> , 2022 ,	5.1	0
19	MAFLD Predicts the Risk of Cardiovascular Disease Better than NAFLD in Asymptomatic Subjects with Health Check-Ups.. <i>Digestive Diseases and Sciences</i> , 2022 ,	4	3
18	The Relation Between Non-alcoholic Fatty Liver Disease and the Risk of Coronary Heart Disease. 2022 , 13,		
17	Plaque progression at coronary CT angiography links non-alcoholic fatty liver disease and cardiovascular events: a prospective single-center study. <i>European Radiology</i> ,	8	

16	Preoperative Evaluation and Management of Patients With Select Chronic Gastrointestinal, Liver, and Renal Diseases. <i>Mayo Clinic Proceedings</i> , 2022 , 97, 1380-1395	6.4	
15	TyG index is positively associated with risk of CHD and coronary atherosclerosis severity among NAFLD patients. <i>Cardiovascular Diabetology</i> , 2022 , 21,	8.7	1
14	Wheat germ improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo-controlled, double-blind clinical trial. <i>Phytotherapy Research</i> ,	6.7	0
13	Shared mechanisms between cardiovascular disease and NAFLD.		1
12	Endothelial Cell Dysfunction and Nonalcoholic Fatty Liver Disease (NAFLD): A Concise Review. 2022 , 11, 2511		3
11	Anticoagulants and Antiplatelet Agents in Cirrhosis. 2022 , 23-48		0
10	Predicci3n de eventos cl3nicos por elasticidad hep3tica y enfermedad renal cr3nica por EHMt en pacientes con diabetes tipo 2. 2022 ,		0
9	CX08005, a Protein Tyrosine Phosphatase 1B Inhibitor, Attenuated Hepatic Lipid Accumulation and Microcirculation Dysfunction Associated with Nonalcoholic Fatty Liver Disease. 2023 , 16, 106		0
8	Association between liver fibrosis and thrombotic or bleeding events in acute coronary syndrome patients. 2022 , 20,		0
7	AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Publish Ahead of Print,		5
6	Association between Cardiovascular Disease and Liver Disease, from a Clinically Pragmatic Perspective as a Cardiologist. 2023 , 15, 748		0
5	Cardiovascular disease in metabolic-associated fatty liver disease. 2023 , 30, 81-86		0
4	Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: Causation or Association. Publish Ahead of Print,		0
3	Sex differences in cardiovascular and all-cause mortality in nonalcoholic fatty liver disease in the US population. 2023 ,		0
2	Metabolic dysfunction-associated fatty liver disease increased the risk of subclinical carotid atherosclerosis in China. 14,		0
1	Erianin alleviated liver steatosis by enhancing Nrf2-mediated VE-cadherin expression in vascular endothelium. 2023 , 175744		0